

Special Issue

Update on Immunotherapies for Cancer

Message from the Guest Editor

The cancer immunotherapy field has made great progress. The initial successes of blocking or antibody-dependent cellular cytotoxicity (ADCC), inducing HER2-specific antibodies, are now complemented in clinical trials by a range of antibody–drug conjugates and bispecific and trispecific antibodies. Their potential for eliciting increasing clinical efficacy via combinatorial approaches will grow significantly with the implementation of new combinations with reduced toxicities and preserved or improved efficacies, such as the recently approved anti-PD1 and anti-LAG3 combination therapy. Tumor-infiltrating T cell therapies have proven their worth in phase 3 trials and been developed into a range of cloned TCR and chimeric antigen receptor cellular therapies. The oldest immunotherapy principle of supplying danger signals within tumors is becoming increasingly refined and diverse with the use of molecular adjuvants, oncolytic virotherapies, and chemotherapy and radiotherapies. In this Special Edition of the IJMS, we will highlight recent breakthroughs and point towards the major challenges remaining.

Guest Editor

Dr. Peter Johannes Holst

Department of Immunology and Microbiology, The Panum Institute, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark

Deadline for manuscript submissions

closed (20 September 2025)



International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



mdpi.com/si/169549

*International Journal of
Molecular Sciences*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
ijms@mdpi.com

[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)





International Journal of Molecular Sciences

an Open Access Journal
by MDPI

Impact Factor 4.9
CiteScore 9.0
Indexed in PubMed



[mdpi.com/journal/
ijms](https://mdpi.com/journal/ijms)



About the Journal

Message from the Editor-in-Chief

The *International Journal of Molecular Sciences (IJMS)* is an open access journal, which was established in 2000. The journal aims to provide a forum for scholarly research on a range of topics, including biochemistry, molecular and cell biology, and molecular biophysics. *IJMS* publishes both original research and review articles, and regularly publishes special issues to highlight advances at the cutting edge of research. We invite you to read recent articles published in *IJMS* and consider publishing your next paper with us.

Editor-in-Chief

Prof. Dr. José L. Quiles
Department of Physiology, Institute of Nutrition and Food Technology
"Jose Mataix", Biomedical Research Center, University of Granada,
Avda. Conocimiento s/n, 18100 Armilla, Granada, Spain

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, MEDLINE, Embase, CAPus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)